Unknown

Dataset Information

0

Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia.


ABSTRACT: Histone deacetylase inhibitors such as vorinostat enhance gemtuzumab ozogamicin efficacy in vitro. We, therefore, investigated vorinostat+gemtuzumab ozogamicin for adults aged 60 years and over with untreated acute myeloid leukemia. We stratified patients into 2 groups (group 1: patients aged ? 70 years and performance status 2-3; group 2: aged 60-69 years with performance status 0-3 or aged ? 70 years and performance status 0-1). Responses were monitored separately in group 2 patients with normal or favorable cytogenetics (group 2A) and other cytogenetics (group 2B). Among 31 patients, 6 (19.4%) achieved complete remission, and one (3.2%) achieved complete remission with incomplete platelet recovery; these patients had a higher median overall survival than non-responders (553 vs. 131 days, P = 0.0026). Response rates were: group 1, one of 10 (10.0%); group 2A, 6 of 13 (46.2%); and group 2B, none of 8 (0%). These data indicate that vorinostat+gemtuzumab ozogamicin has activity that is mostly confined to patients with normal karyotype disease. ClinicalTrial.gov: NCT00673153.

SUBMITTER: Walter RB 

PROVIDER: S-EPMC3342977 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia.

Walter Roland B RB   Medeiros Bruno C BC   Powell Bayard L BL   Schiffer Charles A CA   Appelbaum Frederick R FR   Estey Elihu H EH  

Haematologica 20111201 5


Histone deacetylase inhibitors such as vorinostat enhance gemtuzumab ozogamicin efficacy in vitro. We, therefore, investigated vorinostat+gemtuzumab ozogamicin for adults aged 60 years and over with untreated acute myeloid leukemia. We stratified patients into 2 groups (group 1: patients aged ≥ 70 years and performance status 2-3; group 2: aged 60-69 years with performance status 0-3 or aged ≥ 70 years and performance status 0-1). Responses were monitored separately in group 2 patients with norm  ...[more]

Similar Datasets

| S-EPMC4104771 | biostudies-literature
| S-EPMC6661897 | biostudies-literature
| S-EPMC8469571 | biostudies-literature
| S-EPMC3683663 | biostudies-literature
| S-EPMC7460695 | biostudies-literature
| S-EPMC6331698 | biostudies-literature
| S-EPMC3682338 | biostudies-literature
| S-EPMC4271731 | biostudies-literature
| S-EPMC6824118 | biostudies-literature